UNveiling the MEchanism(s) underlying the switch to mania during antidepressant treatment: The role of glutamate. Project No.: ERANET NEURON II/2018/569/UNMET, principal investigator at the BMC SAS: Daniela Ježová. Duration: 1.7.2019 / 30.6.2023.
The role of specific cell-types of the median raphe in behavior: the excitatory vesicular glutamate transporter 3 and the inhibitory GABA. Project No.: Bilateral project with Hungarian Academy of Sciences, principal investigator at the BMC SAS: Daniela Ježová. Duration: 1.1.2019 / 31.12.2022.
Identification of psychological and somatic markers in relation to vulnerability to stress and analysis of the effectiveness of psychological interventions. Project No.: APVV-17-0451, principal investigator at the BMC SAS: Daniela Ježová. Duration: 1.8.2018 / 31.12.2022.
Bridge between the mental state and neuroendocrine function of mother and her child: the mechanisms involved. Project No.: APVV-18-0283, principal investigator: Daniela Ježová. Duration: 1.7.2019 / 30.3.2023.
Interrelationships between endocrine and mental characteristics of women in reproductive age. Project No.: VEGA 2/0022/19, principal investigator: Daniela Ježová. Duration: 1.1.2019 / 31.12.2022.
Potential risk of use of analogs of endocrine disruptor Bisphenol A: determination of cellular and molecular effects in a spectrum of in vitro gonadal cell cultures. Project No.: APVV-18-0150, principal investigator: Alžbeta Bujňáková Mlynarčíková. Duration: 1.7.2019 / 30.06.2022
Cardiometabolic effects of Mas receptor stimulation by modulation of the renin-angiotensin system – the key role of angiotensin-converting enzyme 2. Project No.: APVV-20-0421, principal investigator: Štefan Zorad. Duration: 1.7.2021 / 30.6.2025.
Regulation of preadipocyte differentiation and adipocyte metabolism by oxidative stress in rat and human tissue culture. Project No.: VEGA 2/0160/20, principal investigator: Štefan Zorad. Duration: 1.1.2020 / 31.12.2022.
Impact of selected metal nanoparticles on steroidogenesis: comparison of in vitro models. Project No.: VEGA 2/0162/20, principal investigator: Soňa Scsuková. Duration: 1.1.2020 / 31.12.2022.
In silico and in vitro investigation of novel nuclear retinoid X receptor (RXR) ligands as potential anti-tumour agents. Project No.: Austrian-Slovakian grant 2019-10-15-009, principal investigator: Július Brtko. Duration: 1.5.2020 / 30.4.2023.
Multidrug resistance of leukemia cells – Phenotype caused by interference of multimodal molecular reasons. Project No.: APVV-19-0093, investigators: Július Brtko, Dana Macejová. Duration: 1.7.2020 / 31.5.2024.
Molecular mechanisms of trialkyl-/triaryltin isothiocyanates’ and carboxylates’ antitumour properties – novel ligands of nuclear retinoid X receptors in rat mammary gland carcinomas and human tumour cell lines. Project No.: APVV-20-0314, principal investigator: Dana Macejová. Duration: 1.7.2021 / 30.6.2025.
Molecular regulatory mechanisms and therapeutic potential of retinoid X receptor activation by triorganotin compounds in relation to breast cancer treatment. Project No.: VEGA 2/0116/21, principal investigator: Dana Macejová. Duration: 1.1.2021 / 31.12.2023.
Potential risk of use of analogs of endocrine disruptor Bisphenol A: Determination of cellular and molecular effects in a spectrum of in vitro gonadal cell cultures. Project No.: APVV-18-0150, principal investigator: Alžbeta Bujňáková Mlynarčíková. Duration: 1.7.2019 / 30.12.2022.
Enhancement of endocannabinoid signaling as a promising target for the treatment of stress-related psychiatric disorders. Project No.: VEGA 2/0158/22, principal investigator: Nataša Hlaváčová. Duration: 1.1.2022/ 30.12.2025.